The primary biomarkers used to diagnose CIRS are: (1) Visual Contrast Sensitivity (VCS) test—abnormally low sensitivity indicating retinal microcirculation dysfunction; (2) HLA-DR genetic susceptibility; (3) Melanocyte-stimulating hormone (MSH)—abnormally low; (4) Cytokine levels—abnormally elevated; (5) TGF-beta-1 (transforming growth factor beta 1)—abnormally elevated. These biomarkers are chosen because they are validated to separate cases from healthy controls and show objective improvement with treatment.